


VIRTUAL
FORMAT

18-19
February 2021



Richard S. Finn

UCLA David Geffen School of Medicine
Signal Transduction and Therapeutics Program,
Jonsson Comprehensive Cancer Center University of California, Los Angeles

Dr Finn is a Professor of Clinical Medicine in the Division of Hematology / Oncology at the UCLA David Geffen School of Medicine and Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA.

He currently splits his time between patient care and laboratory and clinical research. His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer. Dr Finn has served as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatocellular cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics. His work has been published in journals such as the *New England Journal of Medicine*, *The Lancet*, *Journal of Clinical Oncology*, *Lancet Oncology*, *Cancer Research*, *Clinical Cancer Research*, *Hepatology*, *Cancer Cell* and elsewhere. Dr Finn has also given oral presentations at major meetings including American Society of Clinical Oncology (ASCO), European Cancer Conference (ECCO/ ESMO), and the American Association of Cancer Research (AACR) and others. An active cancer researcher, he has been involved in the development of several novel therapeutics in cancer medicine. He has brought several practice changing advances to cancer medicine. With Dr Dennis Slamon, he led the approval of palbociclib (Ibrance), the first CDK 4/6 inhibitor in cancer medicine, from pre-clinical development to global registration.

Dr Finn is a member of ASCO, American Association of Cancer Research (AACR) and the European Society of Medical Oncology (ESMO). He and is on the editorial board of *Clinical Cancer Research*.

Innovation
in Breast Cancer

iBC 2021